Ashwin Balagopal, MD

• Chair, ACTG 5335s
• Investigator ACTG 5329 and ACTG 5334s
• Investigator, Hepatitis Transformative Science Group (Feb 2016)

1077BF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

The A5322 protocol is a long-term observational study, with a planned series of analyses of data to be collected from an...

IMPAACT 2010 is a Phase III, three-arm, randomized, open-label study of HIV-1-infected pregnant women initiating either a...

The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...

This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...

Johns Hopkins University Baltimore-India Clinical Trials Unit